Raymond James analyst David Novak maintained a Buy rating on Ziopharm Oncology (ZIOP) yesterday and set a price target of $5.50. The company’s shares closed last Thursday at $2.42, close to its 52-week low of $1.80.
According to TipRanks.com, Novak is a 3-star analyst with an average return of 7.9% and a 33.3% success rate. Novak covers the Healthcare sector, focusing on stocks such as Catalyst Biosciences, Knight Therapeutics, and Leap Therapeutics.
Ziopharm Oncology has an analyst consensus of Moderate Buy, with a price target consensus of $5.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $5.61 and a one-year low of $1.80. Currently, Ziopharm Oncology has an average volume of 1.58M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of a diverse portfolio of cancer therapies. It focuses on developing products in immuno-oncology that employ novel gene expression, control, and cell technologies for the treatment of cancer. The company was founded on September 9, 2003 and is headquartered in Boston, MA.